Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8135260 | 0.95 | HTT (0.56) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL1363586 | 0.95 | ALDH1A1 (0.59) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL7545592 | 0.93 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL18762322 | 0.93 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL1365591 | 0.93 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL24677830 | 0.93 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL24678064 | 0.93 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL1419528 | 0.93 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL318699 | 0.93 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL5386843 | 0.93 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240351975-A1 | METHODS OF SYNTHESIZING 4-VALYLOXYBUTYRIC ACID | XWPharma Ltd. (KY) | 2024-10-24 | — | — | US | claimed |
| CN-106905428-A | A kind of synthetic method of florfenicol amine artificial antigen | 江南大学 | 2017-06-30 | — | — | CN | claimed |
| CN-106632663-A | Synthetic method of multi-effect triazole artificial antigen | 江南大学 | 2017-05-10 | — | — | CN | claimed |
| EP-0442850-B1 | Esters of acyl L-carnitines with gamma-hydroxybutyric acid and pharmaceutical compositions containing them for inhibiting neuronal degeneration and for the treatment of coma | SIGMA TAU IND FARMACEUTI (IT) | 1994-07-27 | — | — | EP | claimed |
| EP-0442850-A1 | Esters of acyl L-carnitines with gamma-hydroxybutyric acid and pharmaceutical compositions containing them for inhibiting neuronal degeneration and for the treatment of coma | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1991-08-21 | — | — | EP | claimed |
| US-12612357-B2 | Methods of synthesizing 4-valyloxybutyric acid | XWPharma Ltd. (KY) | 2026-04-28 | — | — | US | disclosed |
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4695237-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-4638461-A1 | DUAL LIPID STRUCTURES | Turn Biotechnologies, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250326731-A1 | CATALYST-CONTROLLED SITE-SELECTIVE METHYLENE C-H LACTONIZATION OF DICARBOXYLIC ACIDS | SCRIPPS RESEARCH INST (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4566608-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-0027948-B1 | TETRAHYDRO-FLUORENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | MERCK & CO. INC. (US) | 1984-03-21 | — | — | EP | disclosed |
| US-4356313-A | [(5,6,9a-substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acid esters and their analogs, the parent acids and their salts | MERCK & CO., INC. (US) | 1982-10-26 | — | — | US | disclosed |
| US-4356314-A | [5,6,9A-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids, their analogs, esters, salts, and derivatives | MERCK & CO., INC. (US) | 1982-10-26 | — | — | US | disclosed |
| US-4348320-A | PENICILLIN INTERMEDIATES | MERCK & CO., INC. (US) | 1982-09-07 | — | — | US | disclosed |
| US-4337354-A | BRAIN AND SPINAL CHORD DAMAGE | MERCK & CO., INC. (US) | 1982-06-29 | — | — | US | disclosed |
| US-4317922-A | [(5,6,9a-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids and their analogs, esters, salts and derivatives | MERCK & CO., INC. (US) | 1982-03-02 | — | — | US | disclosed |
| US-4316043-A | ANTIEDEMIC AGENTS | MERCK & CO., INC. (US) | 1982-02-16 | — | — | US | disclosed |
| EP-0027948-A1 | Tetrahydro-fluorene compounds, processes for their preparation and pharmaceutical compositions thereof | MERCK & CO. INC. (US) | 1981-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240351975-A1 | METHODS OF SYNTHESIZING 4-VALYLOXYBUTYRIC ACID | GABBR1, GABBR2, GABRB3 | ALDH1A1 2199/4885MAPK1 3890/4885L3MBTL1 1522/4885 |
| US-20250326731-A1 | CATALYST-CONTROLLED SITE-SELECTIVE METHYLENE C-H LACTONIZATION OF DICARBOXYLIC ACIDS | DNPH1, NISCH, PTMA | ALDH1A1 3847/4885MAPK1 2929/4885L3MBTL1 1390/4885 |
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | ALDH1A1 2764/4885MAPK1 79/4885L3MBTL1 1416/4885 |
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | CD4, HAVCR2, MAVS | ALDH1A1 1512/4885MAPK1 4303/4885L3MBTL1 1204/4885 |
| US-12612357-B2 | Methods of synthesizing 4-valyloxybutyric acid | GABBR1, GABRB1, GABBR2 | ALDH1A1 2627/4885MAPK1 2984/4885L3MBTL1 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.